Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic non-small cell lung cancer (NSCLC) treatment has advanced with targeted therapies against specific oncogenic drivers.
• MET receptor deregulation, via exon 14 skipping mutations or amplification, is a key actionable alteration in a subset of NSCLC patients.
• Approved MET tyrosine kinase inhibitors (TKIs) like capmatinib and tepotinib demonstrate significant efficacy in this molecularly defined group.

Purpose of the Study:

• To provide a comprehensive overview of MET signaling pathways and oncogenic alterations in NSCLC, with a focus on MET exon 14 skipping mutations.
• To review laboratory techniques for detecting MET alterations.
• To summarize current clinical data, ongoing trials, resistance mechanisms, and future strategies for MET-targeted therapies in NSCLC.

Main Methods:

• Literature review of preclinical and clinical studies on MET inhibitors in NSCLC.
• Analysis of data on MET signaling, mutation detection techniques, and clinical trial outcomes.
• Synthesis of information on resistance mechanisms and combinatorial therapeutic approaches.

Main Results:

• MET TKIs have shown high effectiveness in patients with MET exon 14 skipping mutations or amplification.
• Several MET inhibitors are approved, and others are in early-stage clinical trials with promising results.
• Understanding resistance mechanisms is crucial for developing effective long-term treatment strategies.

Conclusions:

• MET-targeted therapies represent a significant advancement for NSCLC patients with specific MET alterations.
• Continued research into novel inhibitors, detection methods, and combination therapies is essential.
• Improving clinical outcomes for MET exon 14-altered NSCLC requires a multi-faceted approach addressing efficacy and resistance.